Sarah Nikiforow
Technical Director, Immune Effector Cell Therapy Program · Mass General Brigham
Credentials: · · · · ·
History
- Present
Connell and O'Reilly Families Cell Manipulation Core Facility · Mass General Brigham
- Present
- 2005–2008
2001–2005
Research
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
New England Journal of Medicine · 2020 · 1,045 citations
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
Cancer Research · 2011 · 511 citations
Journal of Clinical Oncology · 2017 · 419 citations
68 papers
67 papers
66 papers
65 papers
64 papers
62 papers
38 papers
32 papers
Clinical trials
- 2020–2024
CIML NK Cell in Head & Neck Cancer
Principal investigator · Completed · Phase 1
Dana-Farber Cancer Institute
- 2015–2018
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Principal investigator · Completed · Phase 1
Celyad Oncology SA
- 2013
CliniMACS® CD34+ Reagent System for Expanded Access Use
Principal investigator · No longer available
Joseph Antin
- 2026–2031
Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
Site PI · Recruiting · Phase 1
Leslie Kean